Iodine seed implant plus chemotherapy for metastatic pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial studies whether placing iodine-125 radioactive seeds during a procedure, along with chemotherapy, can improve outcomes for people with pancreatic cancer that has spread to other organs. It aims to test a treatment that targets the tumor area while systemic chemotherapy works throughout the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 80 years
- Have stage IV pancreatic ductal adenocarcinoma (pancreatic cancer that has spread) and tumors can be measured on scans
- Have not had any prior chemotherapy, radiation, or surgery
- You must be expected to live more than 6 months
- You need to be medically able to receive chemotherapy (blood counts, liver/kidney tests, and an ECG within limits)
- You must be able to safely undergo an ultrasound-guided procedure to place the iodine seeds
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, IBI343, combined with chemotherapy for people with advanced pancreatic cancer that has gotten worse after first-line treatment. It looks at whether this combination can help shrink tumors or slow cancer growth.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new immunotherapy drug (ivonescimab) combined with targeted radiation and chemotherapy for people with pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
This trial tests a new medicine (IBI363) combined with chemotherapy for people with advanced pancreatic cancer that has grown after their first treatment. The goal is to see if this combination can help shrink or control the cancer longer.
This trial tests a new combination of drugs and radiation for people with pancreatic cancer that has spread. It aims to shrink tumors and improve quality of life by using an immunotherapy drug, two chemotherapies, and precisely targeted radiation.
Hear when a new Metastatic Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.